The patent covers the company’s development of this cell transplant therapy as a treatment for geographic atrophy.
Lineage Cell Therapeutics, Inc. has received U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells” issued by the United States Patent and Trademark Office (USPTO). This patent is expected to expire on July 28, 2036. Until this time or unless it is otherwise liscened, the patent is exclusively licensed to Lineage.
In the news release, the company shared that the patent is issued for RG6501 (OpRegen®), a suspension of human allogeneic RPE cells currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This treatment involves a subretinal delivery of OpRegen, which has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function. The treatment program is being developed under an exclusive worldwide collaboration between Lineage, Roche, and Genentech, a member of the Roche Group.
According to the press release, Lineage Cell Therapeutics CEO, Brian M. Culley said that this shows the company’s ability to further new treatment programs. He is quoted as saying, “This U.S. patent further enhances the value of our lead program, OpRegen, which is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD (NCT05626114). Importantly, Lineage is continuing to demonstrate its ability to benefit from decades of experience in the growth and differentiation of pluripotent cells, while simultaneously inventing and patenting new process development methods, to support long periods of exclusivity to our pipeline of cell transplant programs.”